


## EXPEDITE CANCER DRUG DISCOVERY & DEVELOPMENT

Functional Cell-Based Assays, Cell Lines, & Proteins for Cancer Research






Improved or novel small molecule or biologic therapeutics for cancer is vital. Eurofins DiscoverX® is uniquely positioned with MOA-reflective, cell-based assay solutions, supported with scientific technical expertise, to help you elucidate potent therapeutics for cancer prevention and treatment.

- **MOA-Reflective, Cell-Based Assays** – Homogeneous assays to measure and rank ligand potencies, discover therapeutic MOAs, perform screens, and identify novel compounds
- **Broad Coverage, Comprehensive Menu** – Cell-based functional and binding assay kits, stable cell lines, and purified recombinant enzymes targeting the top drug target classes
- **Ready-to-Use Bioassay Format** – Highly reproducible, robust assays with extraordinary precision and accuracy for seamless and timely implementation for therapeutic development through QC lot release testing programs
- **Custom Development Capabilities** – Leverage over 20 years of expertise and a vast history of generating hundreds of customized assays for drug discovery programs at multiple companies globally

### TARGET FAMILIES OF PRODUCT SOLUTIONS FOR CANCER RESEARCH

Study multiple cancer modalities (tumor growth, angiogenesis, cancer progression and metastasis) and types (lung, pituitary, thyroid, skin, breast, stomach, colon, pancreas, testicular, prostate, ovarian, and more).

Cytokine Receptors	Checkpoint Modulators	Kinases	GPCRs	Nuclear Proteins	Signaling Pathways
IL-1 to -37, G-CSF, GM-CSF, M-CSF, OSM, TNF $\alpha$ , TSLP, ...	CD28/33/47/137/200, CEACAM1, CTLA4, ICOS, LAG3, OX40, PD-1, PD-L1/2, Siglec9, SIRP $\alpha$ , TIGIT, TIM3, ...	>440 including AKT, ATM, AXL, c-Kit, c-MET, c-Ret-GF $\alpha$ 2, DDR1/2, EphA/Bs, ErbBs, Erk, FGFRs, GSK3 $\beta$ , JAK1/2, mTOR, PDGFR $\alpha/\beta$ , PI3K, SIK, TrkA/B/C, ...	A2A, A3, AT1, B1/2, B1/2AR, BB2, BLT1, CB1/2, CCKs, CCRs, CT, CXCRs, EP1-4, ETA/B, FP, FPR, FSHR, GRLN, GPRs, H1-4, IP1, LH, LPAs, LTC4, M1-4, MC1, MCH1, MT1/2, NK1/2, NTS1, OX1/2, P2Ys, PAC1, PAF, PARs, PTH1/2, S1Ps, SSTs, TSH, V1A/B, V2, VPAC1/2, Y4, ...	AR, GR, PPAR $\delta/\gamma$ , THR $\alpha$ , ER $\alpha$ , PR $\alpha/\beta$ , ...	Apoptosis (Bcl2), $\beta$ -catenin/Wnt, CDC25A, DNA damage (p53), NF- $\kappa$ B, I $\kappa$ B, GSK3 $\beta$ , NRF2, PI3K, SREBP, TGF $\beta$ R, TORC/CRTC



For more information on solutions for cancer drug discovery and development, please visit [discoverx.com](https://discoverx.com)